TRI awarded RSC contract to support domestic, international clinical research programs

February 12, 2016

NIAID is working to end the HIV/AIDS epidemic by advancing basic knowledge of the pathogenesis and transmission of HIV, supporting the improvement of therapies for HIV infection and its complications, and supporting the development of HIV/AIDS vaccines and other prevention measures.  NIAID sponsors Phase I, II, III and IV clinical trials to assess the safety and efficacy of therapeutics, vaccines, and other preventive modalities.  Currently, NIAID funds more than 300 HIV/AIDS clinical trials in more than 50 countries at more than 1,000 domestic and international clinical research sites.  

Commenting on the contract award, Nora Lee, TRI's President and CEO expressed, "TRI is ready and eager to continue the mission-critical support services we currently provide to NIAID.  Part of TRI's corporate philosophy is to continually strive to improve our clients' deliverables, something we have achieved and will continue to perform under this contract."

SOURCE Technical Resources International, Inc.